Endo USA, Inc. Issues Voluntary, Nationwide Recall of One Lot of Clonazepam Orally Disintegrating Tablets, USP (C-IV) Lot Number 550147301 Due to Mislabeling: Incorrect Strength on Product Carton
MALVERN, Pa., July 16, 2024 /PRNewswire/ — Endo, Inc (OTCQX: NDOI) (“Endo”), announced today that one of its operating subsidiaries, Endo USA, Inc., is voluntarily recalling one lot of Clonazepam Orally Disintegrating Tablets, USP (C-IV) 0.25 mg tablets, which may also appear as Clonazepam Orally Disintegrating Tablets, USP (C-IV) 0.125 tablets 60-count pack to the consumer level.
Related news for (NDOI)
- Endo Presents Plantar Fibromatosis and Plantar Fasciitis Data at the American Podiatric Medical Association Annual Meeting
- Endo Completes International Pharmaceuticals Business Divestiture
- Endo Champions Men’s Health Month with Education, Awareness, and Outreach
- Endo Expands ADRENALIN® Ready-to-Use Premixed Bag Line with New Concentration
- Endo Reports First-Quarter 2025 Financial Results and Reaffirms 2025 Financial Guidance